Bridgewater Associates, LP cut 51% of VRTX (2026Q1)HIGHSHORTJul 24
Phase 3 trial terminated early - VERTEX A Pilot Study to Evaluate the Use o...HIGHSHORTJun 10
Phase 3 trial terminated early - VERTEX Study to Assess the Efficacy and Sa...HIGHSHORTJun 10
Phase 3 trial terminated early - VERTEX Efficacy of a 12-Week Regimen of Te...HIGHSHORTJun 10
Phase 3 trial terminated early - VERTEX Telaprevir, Peg-IFN-alfa-2a, and RB...HIGHSHORTJun 10
Phase 3 trial terminated early - VERTEX Telaprevir Plus Standard of Care (S...HIGHSHORTJun 10
Phase 3 trial terminated early - VERTEX A Study Evaluating the Long Term Sa...HIGHSHORTJun 10
Phase 3 trial terminated early - VERTEX A Study to Evaluate Efficacy and Sa...HIGHSHORTJun 10